What is the official website of Novartis România ?

The official website of Novartis România is http://www.novartis.com.ro.

What is Novartis România's cybersecurity risk score?

Novartis România has an AI-generated cybersecurity risk score of 755 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis România experienced?

According to Rankiteo, Novartis România currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis România been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis România has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis România have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis România is not certified under SOC 2 Type 1.

Does Novartis România have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis România does not hold a SOC 2 Type 2 certification.

Does Novartis România comply with GDPR ?

According to Rankiteo, Novartis România is not listed as GDPR compliant.

Does Novartis România have PCI DSS certification ?

According to Rankiteo, Novartis România does not currently maintain PCI DSS compliance.

Does Novartis România comply with HIPAA ?

According to Rankiteo, Novartis România is not compliant with HIPAA regulations.

Does Novartis România have ISO 27001 certification ?

According to Rankiteo,Novartis România is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis România operate in ?

Novartis România operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis România have ?

Novartis România employs approximately 94 people worldwide.

Does Novartis România own any subsidiaries ?

Novartis România presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis România have ?

Novartis România's official LinkedIn profile has approximately 211,127 followers.

What is the NAICS classification code for Novartis România ?

Novartis România is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis România have a Crunchbase profile ?

No, Novartis România does not have a profile on Crunchbase.

Does Novartis România have a LinkedIn profile ?

Yes, Novartis România maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-romania.

How many cybersecurity incidents has Novartis România experienced ?

As of June 25, 2026, Rankiteo reports that Novartis România has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis România have ?

Novartis România has an estimated 5,696 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis România faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis România

Boost Score +25 with badge (5 left)

755

/1000

Fair

780

/1000

Fair

Novartis România Vendor Cyber Rating & Cyber Score

novartis.com.ro

Add Your Compliance Badge

La Novartis, scopul nostru este să reimaginăm medicina pentru a îmbunătăți și prelungi viața oamenilor. Folosim știința inovatoare și tehnologiile digitale, pentru a aborda unele dintre cele mai provocatoare probleme de sănătate ale societății. Descoperim și dezvoltăm tratamente revoluționare și găsim noi modalități de a le pune la dispozitia a cât mai multor oameni posibil. Novartis este locul unde știința întâlnește speranța. Descoperim misterele biologiei și dezvoltăm noi tehnologii pentru combaterea bolilor și, ascultându-vă perspectivele și experiențele, creăm medicamente care contează pentru pacienții din întreaga lume. În România, suntem peste 650 de angajați dedicați susținerii pacientilor și sistemului de sănătate. Pentru noi,

Novartis România A.I CyberSecurity Scoring

Scoring History

Novartis România

Novartis România CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis România

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis România Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis România

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis România in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis România in 2026.

Incident Types Novartis România vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis România in 2026.

Incident History - Novartis România (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis România Subsidiaries

Novartis România

Pharmaceutical Manufacturing

Website: http://www.novartis.com.ro

Company Size: 94

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis ItaliaPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Loading…

Novartis România Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Loading…

NEWS

Novartis România CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

February 11, 2019 12:21 AM

Novartis Romania appoints new general manager

Novartis Romania, the local subsidiary of Swiss pharma group Novartis and the third-biggest player on the pharmaceutical market in Romania, appointed the Dutch...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56785

SUMMARY

FlatPress versions prior to commit 10be83c, contains a stored cross-site scripting vulnerability in comment and contact forms where name, URL, and email fields are rendered without proper output encoding in Smarty templates. Attackers can inject arbitrary HTML and JavaScript through these fields to execute malicious scripts in browsers of viewers including administrators, or bypass URL scheme validation to inject javascript: or data: URIs.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 8.2)

cvss3

Base Score: 8.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:L/A:N

cvss4

Base Score: 8.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-54588

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 use the attacker-controlled `HTTP_HOST` request header as the authoritative source for building callback URLs in its OIDC, SAML, and logout authentication flows without any validation. An unauthenticated attacker can poison the `redirect_uri` sent to the Identity Provider, causing the IdP to redirect the victim's authorization code to an attacker-controlled server - resulting in full account takeover with no credentials required. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 9.6)

cvss3

Base Score: 9.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:L

Impact Score

Exploitability

2.8

REFERENCES

CVE-2026-48493

SUMMARY

Snipe-IT is an IT asset/license management system. In versions prior to 8.6.0, a user with only users.edit can send a PATCH to /api/v1/users/{their_own_id} and grant themselves any permission except admin and superuser — for example `assets.view`, `assets.create`, `reports.view`, import, etc. The issue is patched in version 8.6.0.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:H/A:N

Impact Score

4.2

Exploitability

1.2

REFERENCES

CVE-2026-47693

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 are vulnerable to CSV Injection (Formula Injection) in its log export functionality. User-controlled data — specifically the username field — is written to exported CSV files without sanitizing formula trigger characters (=, +, -, @). When an administrator exports activity logs and opens the resulting CSV in a spreadsheet application (Microsoft Excel, LibreOffice Calc, Google Sheets), any formula stored in a username is executed by the application. This can be used for phishing attacks against administrators or data exfiltration. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 6.9)

cvss3

Base Score: 6.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:H/I:L/A:N

Impact Score

4.7

Exploitability

1.7

REFERENCES

CVE-2026-12164

SUMMARY

Fortra File Integrity Monitoring (FIM), formerly Tripwire Enterprise, versions prior to 9.4.0 may assign incorrect or elevated effective permissions to users created by the tetool import command while FIM is running, particularly when the import also creates or changes roles or role-permission relationships.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 4.4)

cvss3

Base Score: 4.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

0.8

REFERENCES

https://www.fortra.com/security/advisories/product-security/fi-2026-010

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…